148 related articles for article (PubMed ID: 15210857)
1. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation.
Liu J; Li C; Qu W; Leslie E; Bonifant CL; Buzard GS; Saavedra JE; Keefer LK; Waalkes MP
Mol Cancer Ther; 2004 Jun; 3(6):709-14. PubMed ID: 15210857
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance.
Maciag AE; Holland RJ; Robert Cheng YS; Rodriguez LG; Saavedra JE; Anderson LM; Keefer LK
Redox Biol; 2013; 1(1):115-24. PubMed ID: 24024144
[TBL] [Abstract][Full Text] [Related]
3. JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways.
Ren Z; Kar S; Wang Z; Wang M; Saavedra JE; Carr BI
J Cell Physiol; 2003 Dec; 197(3):426-34. PubMed ID: 14566972
[TBL] [Abstract][Full Text] [Related]
4. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.
Shami PJ; Saavedra JE; Wang LY; Bonifant CL; Diwan BA; Singh SV; Gu Y; Fox SD; Buzard GS; Citro ML; Waterhouse DJ; Davies KM; Ji X; Keefer LK
Mol Cancer Ther; 2003 Apr; 2(4):409-17. PubMed ID: 12700285
[TBL] [Abstract][Full Text] [Related]
5. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells.
Simeone AM; McMurtry V; Nieves-Alicea R; Saavedra JE; Keefer LK; Johnson MM; Tari AM
Breast Cancer Res; 2008; 10(3):R44. PubMed ID: 18474097
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.
Chakrapani H; Kalathur RC; Maciag AE; Citro ML; Ji X; Keefer LK; Saavedra JE
Bioorg Med Chem; 2008 Nov; 16(22):9764-71. PubMed ID: 18930407
[TBL] [Abstract][Full Text] [Related]
7. Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles.
Kaur I; Terrazas M; Kosak KM; Kern SE; Boucher KM; Shami PJ
J Pharm Pharmacol; 2013 Sep; 65(9):1329-36. PubMed ID: 23927471
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: requirement for Cyp1a1.
Qu W; Cheng L; Dill AL; Saavedra JE; Hong SY; Keefer LK; Waalkes MP
Chem Biol Interact; 2011 Aug; 193(1):88-96. PubMed ID: 21621526
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug.
Findlay VJ; Townsend DM; Saavedra JE; Buzard GS; Citro ML; Keefer LK; Ji X; Tew KD
Mol Pharmacol; 2004 May; 65(5):1070-9. PubMed ID: 15102935
[TBL] [Abstract][Full Text] [Related]
10. Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.
Weidensteiner C; Reichardt W; Shami PJ; Saavedra JE; Keefer LK; Baumer B; Werres A; Jasinski R; Osterberg N; Weyerbrock A
Nitric Oxide; 2013 Apr; 30():17-25. PubMed ID: 23370169
[TBL] [Abstract][Full Text] [Related]
11. Role of human glutathione transferases in biotransformation of the nitric oxide prodrug JS-K.
Sjödin B; Mannervik B
Sci Rep; 2021 Oct; 11(1):20765. PubMed ID: 34675290
[TBL] [Abstract][Full Text] [Related]
12. Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.
Maciag AE; Nandurdikar RS; Hong SY; Chakrapani H; Diwan B; Morris NL; Shami PJ; Shiao YH; Anderson LM; Keefer LK; Saavedra JE
J Med Chem; 2011 Nov; 54(22):7751-8. PubMed ID: 22003962
[TBL] [Abstract][Full Text] [Related]
13. V-PROLI/NO, a nitric oxide donor prodrug, protects liver cells from arsenic-induced toxicity.
Qu W; Liu J; Dill AL; Saavedra JE; Keefer LK; Waalkes MP
Cancer Sci; 2009 Mar; 100(3):382-8. PubMed ID: 19154403
[TBL] [Abstract][Full Text] [Related]
14. The nitric oxide prodrug, V-PYRRO/NO, mitigates arsenic-induced liver cell toxicity and apoptosis.
Qu W; Liu J; Fuquay R; Saavedra JE; Keefer LK; Waalkes MP
Cancer Lett; 2007 Oct; 256(2):238-45. PubMed ID: 17658681
[TBL] [Abstract][Full Text] [Related]
15. JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C).
Shami PJ; Maciag AE; Eddington JK; Udupi V; Kosak KM; Saavedra JE; Keefer LK
Leuk Res; 2009 Nov; 33(11):1525-9. PubMed ID: 19193435
[TBL] [Abstract][Full Text] [Related]
16. The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.
Maciag AE; Saavedra JE; Chakrapani H
Anticancer Agents Med Chem; 2009 Sep; 9(7):798-803. PubMed ID: 19538173
[TBL] [Abstract][Full Text] [Related]
17. JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells.
Udupi V; Yu M; Malaviya S; Saavedra JE; Shami PJ
Leuk Res; 2006 Oct; 30(10):1279-83. PubMed ID: 16439016
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53.
Kitagaki J; Yang Y; Saavedra JE; Colburn NH; Keefer LK; Perantoni AO
Oncogene; 2009 Jan; 28(4):619-24. PubMed ID: 18978812
[TBL] [Abstract][Full Text] [Related]
19. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells.
Laschak M; Spindler KD; Schrader AJ; Hessenauer A; Streicher W; Schrader M; Cronauer MV
BMC Cancer; 2012 Mar; 12():130. PubMed ID: 22462810
[TBL] [Abstract][Full Text] [Related]
20. The Nitric Oxide Prodrug JS-K Induces Ca(2+)-Mediated Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells.
Liu L; Wang D; Wang J; Wang S
J Biochem Mol Toxicol; 2016 Apr; 30(4):192-9. PubMed ID: 26616367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
